HT-1376 Xenograft Model Service for Bladder Cancer

The HT-1376 xenograft model offers a robust, clinically relevant platform for evaluating novel therapeutics against muscle-invasive bladder cancer in vivo. At Alfa Cytology, we provide a fully integrated HT-1376 Xenograft Model Service for Bladder Cancer, combining high-quality cell line authentication, standardized tumor implantation protocols, and comprehensive pharmacodynamic and pharmacokinetic readouts to accelerate your preclinical development pipeline.

Overview of HT-1376 Xenograft Model for Bladder Cancer

The HT-1376 cell line, originally established from a grade 3 transitional cell carcinoma (urothelial carcinoma) resected from a 58-year-old female patient, represents a well-characterized muscle-invasive bladder cancer (MIBC) model. When propagated as subcutaneous xenografts in immunocompromised nude mice, HT-1376 tumors typically exhibit squamous histology with regions of necrosis and maintain a molecular profile that closely resembles the parental 2D culture, making it a reliable surrogate for preclinical drug evaluation. Transcriptomic studies have demonstrated that HT-1376 xenografts retain mixed basal and luminal molecular signatures, with fewer than 200 differentially expressed genes between in vitro and in vivo states, underscoring the model's fidelity for translational research.

In xenograft settings, HT-1376 tumors display moderate growth kinetics, generally requiring approximately 40 days to reach 1,000 mm^3 when initiated with 2x10^6 cells in a 1:1 HBSS-Matrigel suspension. The model has been extensively utilized to assess chemotherapeutic responses---including cisplatin resistance profiles---and to evaluate targeted delivery systems such as peptide-conjugated nanoparticles. Additionally, HT-1376 harbors characteristic 9p21 chromosomal deletions affecting CDKN2A, CDKN2B, and MTAP, providing a genetically defined background for studying cell-cycle dysregulation and exploring synthetic lethality strategies in bladder cancer.

Figure 1. Representative tumor development from bladder cancer. (Sharrow, Allison C, et al., 2020)

Cell Line Information: HT-1376

The following table summarizes the essential characteristics and provenance of the HT-1376 cell line, which serves as the foundational resource for xenograft model construction.

Our Services

Alfa Cytology leverages authenticated HT-1376 cell stocks, rigorous quality control, and standardized xenograft protocols to deliver reproducible tumor growth curves, histopathological validation, and customizable pharmacodynamic endpoints. Our preclinical team ensures seamless integration of the HT-1376 model into your compound profiling workflow, from dose-escalation studies to combination therapy assessments, all conducted under IACUC-approved protocols with comprehensive data reporting.

Workflow of HT-1376 Xenograft Model Construction

Construction of the HT-1376 xenograft model follows a systematic, quality-controlled workflow designed to ensure tumor engraftment consistency, animal welfare compliance, and data reproducibility. Each stage incorporates validated standard operating procedures (SOPs) aligned with preclinical best practices.

1. Cell Line Expansion and Quality Verification: HT-1376 cells are expanded from authenticated, low-passage master stocks under adherent culture conditions in MEM supplemented with 10% FBS. Prior to inoculation, cells undergo mycoplasma testing, viability assessment by trypan blue exclusion (target viability >95%), and STR confirmation to ensure genetic integrity.
2. Cell Harvest and Matrigel Preparation: Exponentially growing cells are harvested using trypsin-EDTA, washed in HBSS, and counted precisely. A 1:1 mixture of HBSS and high-concentration Matrigel is prepared on ice to preserve extracellular matrix integrity, providing a supportive scaffold for initial tumor cell anchorage.
3. Subcutaneous Inoculation: A suspension of 2x10^6 HT-1376 cells in 100 ul total volume (50 ul HBSS + 50 ul Matrigel) is injected subcutaneously into the right flank of athymic nude mice (e.g., 6--8-week-old females) using a 25-gauge needle. Tumor cell density and injection volume are calibrated to optimize engraftment rates while minimizing leakage.
4. Tumor Monitoring and Measurement: Following inoculation, mice are monitored daily for health status and twice weekly for tumor palpation. Once tumors become palpable, caliper measurements are recorded twice weekly; tumor volume is calculated using the modified ellipsoid formula (L x W^2) / 2, where L is the longest axis and W is the perpendicular shortest axis.
5. Endpoint Determination and Tissue Collection: Tumors are typically allowed to grow until they reach approximately 1,000 mm^3 (or per study-specific humane endpoints). At endpoint, mice are humanely euthanized; tumors are excised, weighed, and partitioned for downstream analyses---fresh-frozen for RNA/DNA extraction, formalin-fixed for histopathology (H&E, IHC), or snap-frozen for protein lysate preparation.
6. Data Compilation and Reporting: All tumor growth data, body weight records, and histopathological images are compiled into a standardized study report. Tumor growth inhibition (TGI) is calculated relative to vehicle controls, and statistical significance is determined using appropriate parametric or non-parametric tests.

Figure 2. HT-1376 xenograft model construction workflow.

Case Study-HT-1376 Xenograft Model Development

In a representative preclinical engagement, the HT-1376 xenograft model was employed to evaluate the efficacy of a novel targeted therapeutic agent in a subcutaneous nude mouse setting. Tumors were established using authenticated HT-1376 cells and monitored over a 40-day growth period, during which treatment cohorts received the investigational compound according to a predefined dosing schedule. Comprehensive endpoints included tumor volume regression, body weight monitoring, histopathological examination of H&E-stained sections, and immunohistochemical analysis of proliferation and apoptosis markers. Detailed quantitative results, including tumor growth inhibition rates, pharmacokinetic correlations, and biomarker modulation data, are available upon request under a confidentiality agreement---please contact our scientific team to discuss specific dataset access and customized study designs.

Why Choose Alfa Cytology?

Alfa Cytology delivers a differentiated preclinical service experience built on scientific rigor, operational transparency, and client-centric flexibility. Our HT-1376 xenograft program is designed to generate publication-quality data while accelerating your decision-making timelines.

• Authenticated cell lines with verified STR profiles and mycoplasma-negative certification ensure genetic fidelity across every study.
• Standardized xenograft protocols with documented engraftment rates and consistent tumor growth kinetics reduce experimental variability.
• Customizable study designs accommodating single-agent, combination, and dose-escalation paradigms tailored to your therapeutic hypothesis.
• Comprehensive endpoint portfolio including tumor volume tracking, histopathology, immunohistochemistry, pharmacokinetic sampling, and biomarker analysis.
• IACUC-approved animal welfare programs with humane endpoint criteria and real-time health monitoring aligned with AAALAC guidelines.
• Dedicated project management with milestone-based reporting, ensuring transparent communication and rapid turnaround of draft and final study reports.

Contact Us

Ready to advance your bladder cancer preclinical program with a validated HT-1376 xenograft model? Contact us today to discuss your study objectives, review our capabilities presentation, and receive a customized proposal tailored to your compound and timeline. Please reach out to us today via our inquiry form or email to learn more about our HT-1376 Xenograft Model services.

For research use only. Not intended for any clinical use.